The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.
The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.
Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.
Mycoplasma hyopneumoniae (M. hyopneumoniae) infections continue to result in significant respiratory challenges in the swine industry worldwide. Vaccination for M. hyopneumoniae is commonly utilized, as reduction in bacterial loads and clinical severity in vaccinated pigs have been shown. However, the effect of M. hyopneumoniae vaccination on transmission across different pig populations has been minimally investigated.
Don’t miss any news on PRRS disease control Subscribe now to PRRS.com newsletter
The objective of this study was to evaluate several adjuvants and/or immunomodulators in combination with Ingelvac PRRS MLV and investigate potential clinical or immunological improvements in vivo.
The results of this study confirmed that in a severe heterologous virulent challenge respiratory model, Ingelvac PRRS MLV provided significant levels of protection.
The objective of this report was to summarize the data from 16 independent laboratory trials, which evaluated Ingelvac PRRS and Ingelvac ATP vaccine efficacy in the respiratory model.
Vaccination was efficacious against a wide variety of heterologous challenge strains with varied isolation times, genetic sequences, and relative virulence.
The objective of this study was to evaluate the efficacy of Ingelvac PRRS MLV, Prevacent PRRS and a novel experimental PRRSV MLV vaccine in a pig respiratory challenge model.
Ingelvac PRRS MLV group demonstrated a significant improvement in ADWG and reduction in the level of viremia compared to both the Prevacent PRRS and non-vaccinated control groups during the post-challenge period.
The purpose of this study was to evaluate the potential benefits of an autogenous killed PRRS product when used in combination with Ingelvac PRRS vaccine to protect against PRRSV challenge.
Ingelvac PRRS MLV provided heterologous protection, whereas the use of a killed autogenous PRRS vaccine alone or in combination failed to provide protection or any added benefit.